vasopressin injection technique to preserve ovarian reserve in surgery for unilateral ovarian endometriomas

Conditions: Unilateral Ovarian Endometrioma

Summary: endometriosis is a common disease with an incidence rate of 15% in women of childbearing age, and is a chronic disease that significantly affects women's quality of life by causing two problems: pain and infertility. the usual treatment for ovarian endometrioma is surgery, and the most common surgical method is laparoscopy, however, surgery has the disadvantage of deteriorating ovarian function. previous studies reported that local injection of vasopressin may minimize damage to the ovarian tissue during the surgical procedure. currently, the best way to evaluate ovarian function is to measure amh (anti-mullerian hormone). however, previous studies has not evaluated ovarian function by amh. aim of this study is to compare the anti-mullarian hormone (amh) change in vasopressin-administered patients after unilateral endometrioma surgery. in this study, antimullerian hormone (amh) will be used as an indicator of ovarian function evaluation, and will be evaluated before surgery, 6 and 12 months after surgery. subjects were allocated randomly with stratification of amh level 3.0mg / ml.

endometriosis is a common disease with an incidence rate of 15% in women of childbearing age, and is a chronic disease that significantly affects women's quality of life by causing two problems: pain and infertility. the usual treatment for ovarian endometrioma is surgery, and the most common surgical method is laparoscopy. surgery has the advantage of reducing the pain of ovarian endometrioma and lower recurrence rate compared to other treatment methods, but it also has the disadvantage of deteriorating ovarian function. this is because healthy ovarian tissue adjacent to the ovarian tumor are damaged at the time of surgery, and damage to the ovarian tissue while using an electric cauterizer for hemostasis when removing the ovarian tumor. therefore, various surgical methods have been studied to minimize damage to the ovarian tissue during the surgical procedure including local vasopressin injection into the surgical site. vasopressin is a peptide hormone secreted by the posterior lobe of the pituitary gland, which promotes reabsorption of water in the kidney when administered systemically, but when administered locally, it constricts blood vessels and prevents bleeding such as in esophageal variceal therapy or myomectomy. there are previous studies that demonstrated, vasopressin injection prior to endometrioma resection, the interface between the endometrioma and normal ovarian tissue is dissected, and the amount of deterioration in ovarian function after surgery is reduced compared to the group without vasopressin by reducing the amount of bleeding through vasoconstriction. endometriosis is the most common disease that interferes with pregnancy, and is known to have a significant decrease in ovarian function after surgery compared to other benign ovarian tumors. currently, the best way to evaluate ovarian function is to measure amh (anti-mullerian hormone). in a paper published in jmig in 2014, the degradation of ovarian function was not evaluated as amh. the purpose of this study is to investigate the effect of vasopressin on ovarian function in endometrioma surgery. patients who have obtained consent in advance are divided into a test group that injects vasopressin and a control that excises it without injection. in the test group, everything except the administration of vasopressin at the surgical site immediately before the endometriosis was performed is the same as that of the control group. in this study, antimullerian hormone (amh) will be used as an indicator of ovarian function evaluation, and will be evaluated before surgery, 6 and 12 months after surgery aim of this study is to compare the anti-mullarian hormone (amh) change in vasopressin-administered patients after unilateral endometrioma surgery. in this study, subjects were allocated randomly with stratification of amh level 3.0mg / ml. when α (type 1 error) = 0.05

Eligibility criteria:
inclusion criteria: * subjects undergoing laparoscopic ovarian cyst enucleation for unilateral endometrioma. * 25≤age≤45 * 0.5≤amh≤7 exclusion criteria: * subjects with major medical conditions such as uncontrolled infection, diabetes, severe renal or hepatic disease. * history of hormonal medication use within 2months

Keywords: endometriosis vasopressins anti-mullerian hormone